Amarin Corp Plc (AMRN)

[James364202]

Agree, I thought he had more "zip" than usual. Most important thing he mentioned, IMHO, was the possibly early results from R-It. I don't remember any previous mention that JELIS had wide divergence of graphs at 1 and 1/2 years showing 45% efficacy in subgroup analysis. I'm sure the DMC is not unaware (double negative) that JELIS subgroup with HDL under 40 and Tri over 150 had early and huge efficacy. To put in perspective, I've never seen a CV outcome study, other than JELIS, that had efficacy that high. Should R-It mirror JELIS, the practice of medicine will change!